The global antimicrobial susceptibility testing market is expected to grow at a CAGR of around 6.1% from 2019 to 2027 to reach at $5.09 billion by 2027.
Susceptibility testing is used in the determination of the antimicrobials inhibiting the growth of the bacteria or fungi causing a specific infection. The aim of antimicrobial susceptibility testing is to predict the in vivo success or failure of antibiotic therapy. Tests performed measure the growth response of an isolated organism to a particular drug or drugs. The results of this test help a healthcare practitioner to determine the most effective drug for treatment of infections. The global burden of infectious diseases is resulting into growing need for susceptibility testing and scientists are striving to develop broad spectrum antibiotics and check microbial susceptibility against them.
Here are the top 10 companies operating in Antimicrobial Susceptibility Testing Market –
Established in 1963 and headquartered at l’Etoile, France; bioMérieux S.A. is a producer of in vitro diagnostics solutions and engaged in development of new approaches in the field of diagnostics, immunotherapy, food safety, and nutrition to fight against infectious diseases and cancers. The company produces and markets systems that are used in industrial and clinical applications i.e. for clinical diagnostics, industrial microbiological control – particularly in the agri-food sector, environmental monitoring, veterinary diagnostics, microbial identification and resistance detection. The company manufactures a range of products such as culture media, MIC strips, and automated laboratory instruments for conducting antibiotic susceptibility testing.
The company has direct presence through its production and R&D sites in the U.S., Brazil, France, Spain, Italy, Australia, Germany, India, Belgium and China and through its subsidiaries in Kenya, the U.S, Norway, Serbia, Chile, Mexico, Brazil, Sweden, Argentina, Vietnam, Thailand, India, China, Canada, Turkey, Russia, Italy, Greece, Germany, Belgium, Singapore, Japan, the U.K., Australia, Spain, the Netherlands, and South Africa. The major subsidiaries of the company operating in Antimicrobial Susceptibility Testing (AST) market are BioFire Diagnostics (U.S.), AB bioMérieux (Sweden), and PML Microbiologicals Inc. (U.S.).
Founded in 1969 and headquartered at Washington, D.C., U.S.; Danaher Corporation designs, manufactures, and markets professional, medical, industrial and commercial products and services. The company operates in four business segments namely Life Sciences, Diagnostics, Dental and Environmental and Applied Solutions. The company operates in the AST market through its diagnostics business segment and offers AST products like microbiology systems, identification systems and AST panels.
The company has total 261 manufacturing and distribution facilities – 109 of these facilities are located in the U.S. in over 25 states and 152 are located outside the U.S. in over 30 other countries. The company has 80 facilities for research and development, manufacturing and distribution of life science products.
Becton, Dickinson and Company
Incorporated in 1906 and headquartered at New Jersey, U.S.; Becton, Dickinson and Company is a global medical technology company involved in the development, manufacture and sale of broad range of medical supplies, devices, laboratory equipment and diagnostic products. The company operates in three business segments namely BD Medical, BD Life Sciences and BD Interventional. BD Medical provides medical technologies and devices which are used for improving healthcare delivery. BD Interventional provides vascular, urology, oncology and surgical specialty products. The company operates in the AST market through its BD Life Sciences business segment which provides products to detect a broad range of infectious diseases, and healthcare-associated infections namely diffusion discs and Phoenix systems for automated antimicrobial susceptibility testing.
The company has direct presence in North Carolina, U.S. and has indirect presence outside the U.S. through its R&D sites in China, France, India, Ireland, and Singapore. The company has manufacturing sites in the U.S., Bosnia, Herzegovina, Brazil, Canada, China, Dominican Republic, France, Germany, Hungary, India, Ireland, Israel, Italy, Japan, Malaysia, Mexico, the Netherlands, Singapore, Spain, and the U.K.
Bio-Rad Laboratories, Inc.
Founded in 1952 and headquartered at California, U.S.; Bio-Rad Laboratories, Inc. is engaged in the development, manufacture, and marketing of products used in life science research and clinical diagnosis. The products and solutions of the company are based on technologies to separate, purify, identify, analyze, and amplify biological materials such as cells, bacteria, antibodies, proteins, and nucleic acids. The company operates through two business segments, namely Life Science and Clinical Diagnostics. The life science business segment manufactures and markets reagents, apparatus and laboratory instruments for research techniques, biopharmaceutical production processes and food testing regimes globally. The company operates in AST market through the clinical diagnostics business segment which designs, manufactures, and sells test systems, informatics systems, test kits and specialized quality controls that serve clinical laboratories. The segment offers AST products such as susceptibility testing disks, plates, and AST media.
The company has direct presence through its manufacturing, research and distribution facilities, in the western U.S., France, Switzerland, Germany, Belgium, Switzerland, and Singapore. The company also has direct distribution channels in over 35 countries through subsidiaries, distributors, and agents. The principal manufacturing and research facilities of the company for life sciences segment is located at California, Singapore, and England.
A report into the projected growth of the current Antimicrobial Susceptibility Testing Market by Meticulous Research® has produced some incredible forecasts for the industry. By 2027, it’s expected to have grown at a CAGR of 6.1%, reaching over $5.09 billion .
Thermo Fisher Scientific Inc.
Founded in 2006 and headquartered at Massachusetts, U.S.; Thermo Fisher Scientific Inc. provides analytical instruments, laboratory equipment, lab services, and diagnostics instruments through five brands, namely, Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services. The company operates through four business segments, namely, laboratory products & services, life sciences solutions, analytical instruments, and specialty diagnostics. Through the microbiology business of the specialty diagnostics business segment, the company offers antimicrobial susceptibility testing products such as automated and manual AST instruments and plates, media and reagents for AST, and others.
The company’s specialty diagnostics business segment has direct presence in the U.S. through its operational offices, engineering sites, laboratories, and production sites which are present in Virginia, Kansas, Michigan, New Hampshire and California, within the U.S., and in Sweden, Germany, the U.K., France, Switzerland, Finland, China, Canada and Japan. The segment offers products to customers in healthcare, clinical, pharmaceutical, industrial and food safety laboratories. TREK Diagnostics Systems, Inc. (U.S.) and Oxoid Limited (U.K.) are the subsidiaries operating in the AST business.
HiMedia Laboratories Pvt. Ltd.
Founded in 1973 and headquartered at Mumbai, India; HiMedia Laboratories Pvt. Ltd. is a manufacturer of range of chromogenic and vegetable hydrolysate-based media products. The company offers products for animal cell culture, plant tissue culture, and molecular biology. The company operates in the AST market by offering media and antimicrobial susceptibility tests for the selection of appropriate antimicrobial agents.
The company has direct presence in the U.S. and Germany through its subsidiary HiMedia Laboratories, LLC (U.S.) and HiMedia Laboratories GmbH (Germany), and indirect presence through its distribution partners in other parts of North America and Europe.
Merlin Diagnostika GmbH
Founded in 1990 and headquartered at North Rhine-Westphalia, Germany; Merlin Diagnostika GmbH, a subsidiary of Bruker Corporation (U.S.) is a developer and manufacturer of products for microbial identification and susceptibility testing of bacteria and yeasts. The company offers automated or manual susceptibility testing products such as microplates, MIC strips, discs under Bruker Scientific Instruments (BSI) business segment of Bruker Corporation through the MICRONAUT brand.
The company has indirect presence through its distribution partners in Bulgaria, France, Great Britain, Greece, Italy, Malaysia, the Netherlands, Norway, Austria, Russia, and United Arab Emirates and direct presence through its manufacturing sites in Germany.
Founded in 1668 and headquartered at Darmstadt, Germany; Merck KGaA is engaged in the manufacturing of products and services for genomics, proteomics, and cellular analysis. The company operates in three business segments namely healthcare, life science, and performance materials. The company offers antimicrobial susceptibility testing products in the life science business segments and through its subsidiaries Sigma-Aldrich Corporation (U.S.) and Millipore Corporation (U.S.). The AST product offerings include AST media and susceptibility testing discs.
The life science business segment through its production and distribution sites has direct presence across Europe, North America, Asia-Pacific, Latin America, and the Middle East and Africa.
Accelerate Diagnostics, Inc.
Incorporated in 1982 and headquartered at Arizona, U.S., Accelerate Diagnostics, Inc. is engaged in providing solutions that improve patient outcomes and lower healthcare costs through the fast diagnosis of serious infections. The company operates in AST market by offering Accelerate Pheno system, a vitro diagnostic platform intended for the identification and antibiotic susceptibility testing of pathogens. The prominent end users of the company are hospitals, clinical laboratories, and healthcare providers.
The company has direct presence through its subsidiaries in the Netherlands, France, Germany, Italy, Spain, Russia, and the U.K. and indirect presence through its distributors outside the U.S. and Europe.
Founded in 1988 and headquartered at Polverara, Italy; Alifax S.r.l. is specialized in the development, production and distribution of clinical diagnostic instrumentation for laboratory automation for the determination of the Erythrocyte Sedimentation Rate (ESR) and rapid bacterial culture, antimicrobial susceptibility testing, and multi-drug resistant organisms (MDRO) screening. The company provides instruments for ESR line, collection devices, sample transportation, and bacteriology line like automated AST systems namely SIDECAR, Alfred 60/AST, and HB&L.
The company through subsidiaries has direct presence in Russia, Spain, China, U.A.E, and Brazil and through its production sites in Brazil, China, Italy, Russia, and Spain. The company through its distributors has indirect presence in more than 100 countries worldwide.
Popular Mentions: Creative Diagnostics, Synbiosis, and Zhuhai DL Biotech Co., Ltd.
Authoritative Research on the Antimicrobial Susceptibility Testing Market – Global Opportunity Analysis and Industry Forecast (2019-2027)
Need more information? Meticulous Research®’s new report covers each of these companies in much more detail, providing analysis on the following:
- Recent financial performance
- Key products
- Significant company strategies
- Partnerships and acquisitions
The Comprehensive report provides global market size estimates, market share analysis, revenue numbers, and coverage of key issues and trends.
Please download report pages and learn more: